Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Consensus and Guidelines · November 03, 2016

European Decision Algorithms and Therapy Recommendations in LDL-C Lowering in Patients at Very High Cardiovascular Risk

European Heart Journal

 

Additional Info

European Heart Journal
European Society of Cardiology/European Atherosclerosis Society Task Force Consensus Statement on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Practical Guidance for Use in Patients at Very High Cardiovascular Risk
Eur Heart J 2016 Oct 27;[EPub Ahead of Print], U Landmesser, M John Chapman, M Farnier, B Gencer, S Gielen, GK Hovingh, TF Lüscher, D Sinning, L Tokgözoğlu, O Wiklund, JL Zamorano, FJ Pinto, AL Catapano

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading